% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Muranen:276076,
      author       = {T. A. Muranen and A. Morra and S. Khan and D. R. Barnes and
                      M. K. Bolla and J. Dennis and R. Keeman and G. Leslie and M.
                      T. Parsons and Q. Wang and T. U. Ahearn and K. Aittomäki
                      and I. L. Andrulis and B. K. Arun and S. Behrens$^*$ and K.
                      Bialkowska and S. E. Bojesen and N. J. Camp and J.
                      Chang-Claude$^*$ and K. Czene and P. Devilee and S. M.
                      Domchek and A. M. Dunning and C. Engel and D. G. Evans and
                      M. Gago-Dominguez and M. García-Closas and A.-M. Gerdes and
                      G. Glendon and P. Guénel and E. Hahnen and U. Hamann$^*$
                      and H. Hanson and M. J. Hooning and R. Hoppe and L. Izatt
                      and A. Jakubowska and P. A. James and V. N. Kristensen and
                      F. Lalloo and G. J. Lindeman and A. Mannermaa and S.
                      Margolin and S. L. Neuhausen and W. G. Newman and P.
                      Peterlongo and K.-A. Phillips and M. A. Pujana and J.
                      Rantala and K. Rønlund and E. Saloustros and R. K.
                      Schmutzler and A. Schneeweiss and C. F. Singer and M.
                      Suvanto and Y. Y. Tan and M. R. Teixeira and M. Thomassen
                      and M. Tischkowitz and V. Tripathi and B. Wappenschmidt and
                      E. Zhao and D. F. Easton and A. C. Antoniou and G.
                      Chenevix-Trench and P. D. P. Pharoah and M. K. Schmidt and
                      C. Blomqvist and H. Nevanlinna},
      collaboration = {H. investigators},
      title        = {{PREDICT} validity for prognosis of breast cancer patients
                      with pathogenic {BRCA}1/2 variants.},
      journal      = {npj Breast cancer},
      volume       = {9},
      number       = {1},
      issn         = {2374-4677},
      address      = {London},
      publisher    = {Nature Publ. Group},
      reportid     = {DKFZ-2023-00982},
      pages        = {37},
      year         = {2023},
      abstract     = {We assessed the PREDICT v 2.2 for prognosis of breast
                      cancer patients with pathogenic germline BRCA1 and BRCA2
                      variants, using follow-up data from 5453 BRCA1/2 carriers
                      from the Consortium of Investigators of Modifiers of BRCA1/2
                      (CIMBA) and the Breast Cancer Association Consortium (BCAC).
                      PREDICT for estrogen receptor (ER)-negative breast cancer
                      had modest discrimination for BRCA1 carrier patients overall
                      (Gönen $\&$ Heller unbiased concordance 0.65 in CIMBA, 0.64
                      in BCAC), but it distinguished clearly the high-mortality
                      group from lower risk categories. In an analysis of low to
                      high risk categories by PREDICT score percentiles, the
                      observed mortality was consistently lower than the expected
                      mortality, but the confidence intervals always included the
                      calibration slope. Altogether, our results encourage the use
                      of the PREDICT ER-negative model in management of breast
                      cancer patients with germline BRCA1 variants. For the
                      PREDICT ER-positive model, the discrimination was slightly
                      lower in BRCA2 variant carriers (concordance 0.60 in CIMBA,
                      0.65 in BCAC). Especially, inclusion of the tumor grade
                      distorted the prognostic estimates. The breast cancer
                      mortality of BRCA2 carriers was underestimated at the low
                      end of the PREDICT score distribution, whereas at the high
                      end, the mortality was overestimated. These data suggest
                      that BRCA2 status should also be taken into consideration
                      with tumor characteristics, when estimating the prognosis of
                      ER-positive breast cancer patients.},
      cin          = {C020 / B072 / B070},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331 / I:(DE-He78)B072-20160331 /
                      I:(DE-He78)B070-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37173335},
      pmc          = {pmc:PMC10182045},
      doi          = {10.1038/s41523-023-00546-x},
      url          = {https://inrepo02.dkfz.de/record/276076},
}